Merck KGaA, Darmstadt, Germany Selects ArcherDX, Inc. for Strategic Global Companion Diagnostic Test Development Collaboration https://archerdx.com/merck-kgaa-darmstadt-germany-selects-archerdx-inc-for-strategic-global-companion-diagnostic-test-development-collaboration/

Merck KGaA, Darmstadt, Germany Selects ArcherDX, Inc. for Strategic Global Companion Diagnostic Test Development Collaboration October 3, 2018 BOULDER, CO-ArcherDX, a molecular technology company dedicated […]
Washington University, ArcherDX, Inc. partner for MRD in pediatric AML sequencing study https://archerdx.com/washington-university-archerdx-inc-partner-for-mrd-in-pediatric-aml-sequencing-study/

Washington University, ArcherDX, Inc. partner for MRD in pediatric AML sequencing study April 12, 2018 BOULDER, CO-Washington University in St. Louis and ArcherDX, Inc. will […]
ArcherDX, Inc. and Ambry Genetics to provide immune repertoire and CAR-T- related sequencing services https://archerdx.com/archerdx-inc-and-ambry-genetics-to-provide-immune-repertoire-and-car-t-related-sequencing-services/

ArcherDX, Inc. and Ambry Genetics to provide immune repertoire and CAR-T- related sequencing services Partnership accelerates the development of promising new immunotherapies March 26, 2018 […]
ArcherDX, Inc. Closes $35 Million Series A Financing https://archerdx.com/archerdx-inc-closes-35-million-series-a-financing/

ArcherDX, Inc. Closes $35 Million Series A Financing March 20, 2018 BOULDER, CO—ArcherDX, Inc., the leader in NGS-based gene fusion detection tests, announced today that […]